Business Description

Intercept Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
Compare
Compare
Traded in other countries / regions
I4P.GermanyICPT.MexicoICPT.USA Description
Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.48 | |||||
Equity-to-Asset | 0.19 | |||||
Debt-to-Equity | 3.09 | |||||
Debt-to-EBITDA | -3.07 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -3.5 | |||||
Beneish M-Score | -0.06 | |||||
WACC vs ROIC |
Growth Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 21.7 | |||||
3-Year EBITDA Growth Rate | 50.8 | |||||
3-Year EPS without NRI Growth Rate | 35.8 | |||||
3-Year FCF Growth Rate | 46.2 | |||||
Future 3-5Y Total Revenue Growth Rate | 3.3 |
Momentum Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 67.33 | |||||
9-Day RSI | 68.56 | |||||
14-Day RSI | 65.92 | |||||
6-1 Month Momentum % | -3.06 | |||||
12-1 Month Momentum % | -20.4 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.46 | |||||
Quick Ratio | 2.46 | |||||
Cash Ratio | 2.22 | |||||
Days Sales Outstanding | 34.53 | |||||
Days Payable | 1459.9 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 0.1 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 99.07 | |||||
Operating Margin % | -4.31 | |||||
Net Margin % | 50.42 | |||||
ROE % | Neg. Equity | |||||
ROA % | 39.51 | |||||
ROIC % | -22.03 | |||||
ROC (Joel Greenblatt) % | -1613.23 | |||||
ROCE % | -30.79 |
GF Value Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 3.13 | |||||
Price-to-Owner-Earnings | 2.62 | |||||
PS Ratio | 1.34 | |||||
PB Ratio | 6.9 | |||||
Price-to-Tangible-Book | 6.9 | |||||
EV-to-EBIT | -5.52 | |||||
EV-to-Forward-EBIT | -19.44 | |||||
EV-to-EBITDA | -5.58 | |||||
EV-to-Forward-EBITDA | -20.09 | |||||
EV-to-Revenue | 1.48 | |||||
EV-to-Forward-Revenue | 1.87 | |||||
EV-to-FCF | -33.09 | |||||
Price-to-Median-PS-Value | 0.06 | |||||
Price-to-Net-Current-Asset-Value | 7.94 | |||||
Price-to-Net-Cash | 19.09 | |||||
Earnings Yield (Greenblatt) % | -18.12 |